WASHINGTON, DC—The Food & Drug Administration's advisors voted 6-4 against expanding the use of the Johnson & Johnson's drug Xarelto.
The blood thinner has already been approved in the U.S. to reduce the risk of blood clots in patients who have undergone knee or hip replacement surgery and prevent strokes in people with atrial fibrillation not caused by a heart valve problem, according a report on NJ.com.